Sas G, Pepper D S, Cash J D
Br J Haematol. 1975 Jul;30(3):265-72. doi: 10.1111/j.1365-2141.1975.tb00541.x.
Studies on antithrombin III (AT-III) were made by a modification of the two dimensional crossed immunoelectrophoresis technique and gel filtration. Mixing various quantities of heparin with agarose in the first phase of electrophoresis, AT-III from normal human plasma and serum revealed a heterogeneity which depended on the heparin concentration in the agarose gel. At heparin concentrations higher than 16 u/ml, AT-III displayed three components with different electrophoretic mobilities. The component with the highest mobility (designated immunoantithrombin III1 : IAT-III1) dominated in plasma. In normal serum, however, the quantity of this component was decreased and the two other peaks with a slower electrophoretic mobility (IAT-III2 and IAT-III3) became more evident. Normal human plasma and serum were filtered on Sephadex G-200 and the AT-III concentration measured in the fractions by rocket immunoelectrophoresis. The peaks of AT-111 were found in the same fractions for both plasma and serum and were coincident with the albumin peak of the plasma proteins. However, in the case of serum the AT-III concentration decreased less sharply in those fractions with higher molecular weight than in the corresponding plasma fractions. Analysis of these fractions by crossed immunoelectrophoresis revealed that the two components with slower electrophoretic mobility (IAT-III2 and IAT-III3) had higher molecular size than IAT-III1, that the concentration of IAT-III2 and IAT-III3 was significantly higher in serum, and that the high molecular weight components in plasma and serum were qualitatively identical. It is concluded that high molecular weight complexes between AT-III and activated coagulation factors may be present in normally circulating blood and that their detection and possibly quantitation can be achieved using the heparin/agarose crossed immunoelectrophoresis system.
通过对二维交叉免疫电泳技术和凝胶过滤技术进行改进,开展了抗凝血酶III(AT-III)的研究。在电泳的第一阶段,将不同量的肝素与琼脂糖混合,正常人血浆和血清中的AT-III呈现出异质性,这取决于琼脂糖凝胶中的肝素浓度。当肝素浓度高于16单位/毫升时,AT-III显示出三种具有不同电泳迁移率的成分。迁移率最高的成分(称为免疫抗凝血酶III1:IAT-III1)在血浆中占主导地位。然而,在正常血清中,该成分的量减少,另外两个电泳迁移率较慢的峰(IAT-III2和IAT-III3)变得更加明显。将正常人血浆和血清在葡聚糖凝胶G-200上进行过滤,并通过火箭免疫电泳测定各组分中的AT-III浓度。血浆和血清中AT-III的峰出现在相同的组分中,并且与血浆蛋白的白蛋白峰一致。然而,就血清而言,在分子量较高的那些组分中,AT-III浓度的下降比相应血浆组分中的下降要平缓。通过交叉免疫电泳对这些组分进行分析表明,电泳迁移率较慢的两个成分(IAT-III2和IAT-III3)的分子大小比IAT-III1大,IAT-III2和IAT-III3在血清中的浓度明显更高,并且血浆和血清中的高分子量成分在性质上是相同的。得出的结论是,AT-III与活化凝血因子之间的高分子量复合物可能存在于正常循环血液中,并且使用肝素/琼脂糖交叉免疫电泳系统可以实现对它们的检测以及可能的定量分析。